The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Subscribe To Our Newsletter & Stay Updated
